▁British 8.5703125
▁Bi 8.046875
ote 1.810546875
ch 0.12213134765625
▁Pl 6.46875
c 2.4609375
, 2.716796875
▁a 0.9287109375
▁leading 2.234375
▁bi 2.17578125
ote 0.8115234375
chn 0.190673828125
ology 0.001399993896484375
▁company 0.1412353515625
, 1.462890625
▁has 1.6669921875
▁triumph 11.125
ed 0.2186279296875
▁in 0.78125
▁its 1.4599609375
▁quest 3.955078125
▁to 0.1798095703125
▁develop 2.3359375
▁a 0.57177734375
▁ground 4.140625
bre 1.3359375
aking 0.00015044212341308594
▁cancer 3.2578125
▁drug 1.8076171875
, 1.8173828125
▁Mar 9.7265625
im 5.09765625
ast 0.0184173583984375
at 2.9802322387695312e-05
. 1.0380859375
▁Despite 6.51171875
▁its 3.69921875
▁success 1.8525390625
▁in 2.326171875
▁early 4.83984375
▁clin 0.97705078125
ical 0.000896453857421875
▁tri 0.07635498046875
als 0.00011610984802246094
, 0.1070556640625
▁the 0.60791015625
▁company 0.6318359375
▁faces 2.458984375
▁several 3.29296875
▁obst 1.716796875
acles 0.0002512931823730469
▁on 2.82421875
▁its 0.44873046875
▁path 0.734375
▁to 0.0955810546875
▁transform 5.98828125
ing 0.282470703125
▁this 2.638671875
▁potential 2.70703125
▁break 2.03515625
through 0.0007886886596679688
▁into 0.30712890625
▁a 0.173583984375
▁block 4.484375
b 0.0016918182373046875
uster 0.0013751983642578125
▁drug 0.77099609375
. 0.1751708984375
<0x0A> 0.630859375
Mar 2.13671875
im 0.002750396728515625
ast 0.0004303455352783203
at 0.0010309219360351562
▁targets 5.640625
▁an 2.470703125
▁en 0.2138671875
zym 8.26120376586914e-05
e 0.00128173828125
▁known 2.0625
▁as 0.0049285888671875
▁metal 4.078125
lo 0.00664520263671875
prote 0.1226806640625
ase 2.150390625
, 0.8115234375
▁responsible 5.3515625
▁for 0.0007457733154296875
▁reg 2.609375
ulating 0.002895355224609375
▁the 0.953125
▁growth 1.36328125
▁and 0.58447265625
▁spread 0.72705078125
▁of 0.005542755126953125
▁cancer 0.2462158203125
ous 2.00390625
▁cells 0.405517578125
. 0.1895751953125
▁Enc 7.9375
ou 0.031768798828125
rag 0.00217437744140625
ingly 1.5869140625
, 0.0049285888671875
▁initial 2.93359375
▁tri 1.2744140625
als 7.82012939453125e-05
▁have 0.72021484375
▁shown 0.875
▁prom 1.478515625
ising 7.200241088867188e-05
▁results 0.057586669921875
▁in 0.98828125
▁in 4.29296875
hib 0.00461578369140625
iting 0.0013570785522460938
▁the 0.399169921875
▁pro 2.4140625
gression 0.32666015625
▁of 0.0201416015625
▁various 2.716796875
▁solid 4.48828125
▁tum 0.1055908203125
or 3.53125
▁types 1.2177734375
. 1.4755859375
▁The 2.63671875
▁drug 0.716796875
▁has 0.85888671875
▁exhib 5.19921875
ited 0.000186920166015625
▁the 4.15234375
▁ability 0.77490234375
▁to 0.0008740425109863281
▁restrict 7.09765625
▁tum 1.39453125
or 0.039764404296875
▁invasion 5.58984375
▁and 0.6552734375
▁met 0.475830078125
ast 0.0012369155883789062
asis 0.036956787109375
, 0.40380859375
▁offering 3.658203125
▁hope 1.068359375
▁for 0.626953125
▁millions 3.822265625
▁of 0.12200927734375
▁patients 1.2490234375
▁world 1.1494140625
wide 0.0002655982971191406
. 0.3662109375
<0x0A> 0.08258056640625
However 0.87353515625
, 0.00029087066650390625
▁British 1.5712890625
▁Bi 0.0017633438110351562
ote 0.00018489360809326172
ch 0.0020084381103515625
▁must 3.05859375
▁confront 4.14453125
▁hur 6.12109375
d 3.6954879760742188e-06
les 0.0011539459228515625
▁to 2.517578125
▁gain 4.66015625
▁appro 1.5576171875
val 2.4080276489257812e-05
▁for 1.02734375
▁Mar 1.353515625
im 0.002330780029296875
ast 0.00022089481353759766
at 0.0008878707885742188
' 3.125
s 0.00030350685119628906
▁commercial 0.955078125
▁use 1.4677734375
. 0.1077880859375
▁First 2.763671875
, 1.8046875
▁the 0.5029296875
▁company 0.46484375
▁must 0.38330078125
▁successfully 4.15625
▁navigate 0.9052734375
▁the 0.300048828125
▁rig 2.26953125
orous 0.00865936279296875
▁regul 0.8701171875
atory 2.300739288330078e-05
▁process 0.79443359375
▁to 2.9453125
▁demonstrate 2.6328125
▁not 7.7578125
▁only 0.060699462890625
▁the 0.3984375
▁drug 0.38232421875
' 0.0215606689453125
s 2.8133392333984375e-05
▁effect 2.6171875
iveness 0.001850128173828125
▁but 0.308837890625
▁also 0.090576171875
▁its 0.0298309326171875
▁safety 0.0694580078125
. 0.974609375
▁The 2.494140625
▁company 2.494140625
▁faces 3.486328125
▁the 1.6064453125
▁challenge 0.705078125
▁of 0.00142669677734375
▁conduct 3.77734375
ing 4.887580871582031e-05
▁more 3.76171875
▁extensive 1.1181640625
▁clin 0.6201171875
ical 7.128715515136719e-05
▁tri 0.024749755859375
als 7.152557373046875e-07
▁to 0.630859375
▁meet 3.875
▁the 0.91455078125
▁string 2.033203125
ent 0.00013744831085205078
▁requirements 0.810546875
▁of 0.40625
▁regul 0.62841796875
atory 0.17724609375
▁authorities 1.0390625
. 0.42919921875
<0x0A> 0.2198486328125
Add 2.25
itionally 0.0083465576171875
, 7.212162017822266e-05
▁British 0.62548828125
▁Bi 0.0021572113037109375
ote 3.0994415283203125e-06
ch 0.0005273818969726562
▁must 0.69091796875
▁address 3.181640625
▁concerns 2.734375
▁surrounding 2.62109375
▁potential 3.8359375
▁side 0.4169921875
▁effects 0.0030670166015625
. 1.89453125
▁The 2.14453125
▁drug 0.583984375
▁has 1.046875
▁demonstrated 3.20703125
▁m 4.0546875
ild 0.0007243156433105469
▁g 2.810546875
astro 0.023406982421875
int 0.005970001220703125
est 7.271766662597656e-06
inal 2.384185791015625e-06
▁issues 3.111328125
, 1.3876953125
▁such 1.853515625
▁as 0.0001271963119506836
▁di 1.1083984375
arr 3.993511199951172e-05
he 0.006824493408203125
a 4.279613494873047e-05
▁and 0.54052734375
▁n 0.6572265625
ause 2.6464462280273438e-05
a 9.822845458984375e-05
, 0.1199951171875
▁which 1.5107421875
▁require 3.560546875
▁further 0.859375
▁investigation 1.01171875
. 0.845703125
▁Mit 6.921875
ig 0.00018787384033203125
ating 0.0401611328125
▁these 0.2020263671875
▁effects 2.6796875
▁will 1.703125
▁be 0.2177734375
▁essential 1.8828125
▁to 0.67041015625
▁ensure 2.52734375
▁patient 1.5322265625
▁well 5.6875
- 0.12939453125
be 9.167194366455078e-05
ing 3.981590270996094e-05
▁and 0.2783203125
▁gain 1.7724609375
▁accept 3.04296875
ance 0.0024051666259765625
▁from 0.73779296875
▁regul 0.75537109375
ators 1.0849609375
▁who 7.40625
▁prior 2.078125
it 3.3974647521972656e-05
ize 0.0017910003662109375
▁patients 5.0859375
' 0.0220184326171875
▁safety 0.1771240234375
▁and 2.822265625
▁quality 2.99609375
▁of 0.00514984130859375
▁life 0.01453399658203125
. 0.06463623046875
<0x0A> 0.009368896484375
F 2.490234375
ur 0.059539794921875
ther 5.2094459533691406e-05
▁challeng 3.435546875
es 0.0013484954833984375
▁emer 4.3984375
ge 0.00782012939453125
▁in 0.79736328125
▁the 0.54052734375
▁form 0.48388671875
▁of 0.0023822784423828125
▁market 3.87890625
▁competition 0.222900390625
. 0.2108154296875
▁Despite 2.232421875
▁Mar 1.6376953125
im 0.0018148422241210938
ast 0.00047016143798828125
at 0.00021648406982421875
' 0.00955963134765625
s 0.0001882314682006836
▁potential 0.8251953125
, 1.4091796875
▁numerous 4.2890625
▁existing 4.39453125
▁treat 1.5830078125
ments 9.059906005859375e-06
▁have 3.453125
▁established 2.416015625
▁themselves 1.1884765625
▁in 0.79638671875
▁the 0.0572509765625
▁on 2.166015625
col 0.0085601806640625
ogy 4.3272972106933594e-05
▁field 2.3046875
. 0.7509765625
▁The 2.833984375
▁drug 1.5849609375
▁must 1.212890625
▁prove 2.435546875
▁its 0.337158203125
▁superior 0.78125
ity 0.01052093505859375
▁over 1.451171875
▁current 2.970703125
▁ther 1.2626953125
ap 0.001483917236328125
ies 4.291534423828125e-06
▁to 0.44921875
▁persu 4.35546875
ade 5.316734313964844e-05
▁phys 1.224609375
icians 0.0002034902572631836
▁and 0.53271484375
▁patients 0.35302734375
▁to 0.232177734375
▁switch 2.052734375
▁to 0.7802734375
▁Mar 1.5634765625
im 0.0010328292846679688
ast 0.00023758411407470703
at 0.0001232624053955078
. 0.08807373046875
▁Ad 8.5546875
van 1.1357421875
c 1.8916015625
ements 0.0004286766052246094
▁in 0.044647216796875
▁personal 4.12890625
ized 0.004901885986328125
▁medicine 0.0787353515625
▁and 1.283203125
▁target 1.8525390625
ed 0.0076446533203125
▁ther 0.156005859375
ap 0.06890869140625
ies 4.0531158447265625e-06
▁present 4.06640625
▁considerable 7.1640625
▁obst 1.283203125
acles 0.00029087066650390625
▁in 3.376953125
▁establish 3.75390625
ing 3.921985626220703e-05
▁Mar 0.77490234375
im 0.0012426376342773438
ast 0.0003666877746582031
at 0.00044727325439453125
▁as 0.71044921875
▁a 0.55029296875
▁true 8.109375
▁game 1.0126953125
ch 4.9375
anger 0.0006880760192871094
. 0.4677734375
<0x0A> 0.03460693359375
Fin 3.091796875
ally 0.10205078125
, 0.0002903938293457031
▁British 0.489990234375
▁Bi 0.001590728759765625
ote 6.4373016357421875e-06
ch 0.00043082237243652344
▁must 0.373291015625
▁strateg 5.8203125
ize 0.63330078125
▁efficient 7.3515625
▁manufact 2.455078125
uring 0.003753662109375
▁and 0.921875
▁distribution 0.331787109375
▁to 1.9365234375
▁achieve 4.4140625
▁w 2.90234375
ides 7.033348083496094e-06
p 0.00112152099609375
read 1.3113021850585938e-06
▁ad 1.8349609375
option 0.0006694793701171875
▁and 2.931640625
▁overcome 6.7421875
▁pr 4.99609375
icing 0.000354766845703125
▁hur 2.48046875
d 9.5367431640625e-07
les 5.555152893066406e-05
. 0.07489013671875
▁The 0.880859375
▁successful 6.33984375
▁production 2.19921875
▁and 0.493896484375
▁distribution 0.736328125
▁of 0.005786895751953125
▁Mar 0.458740234375
im 0.0008645057678222656
ast 0.0002791881561279297
at 0.0001423358917236328
▁on 3.208984375
▁a 0.01495361328125
▁large 0.681640625
▁scale 0.00605010986328125
▁will 0.705078125
▁rely 5.453125
▁on 0.07818603515625
▁efficient 2.845703125
▁supply 1.40625
▁ch 0.80419921875
ains 1.2636184692382812e-05
▁and 0.77734375
▁partners 2.890625
hips 0.01103973388671875
▁with 0.11688232421875
▁ph 1.6259765625
arma 0.01177215576171875
ce 0.048614501953125
ut 1.1920928955078125e-06
ical 2.586841583251953e-05
▁companies 0.265380859375
▁to 2.23828125
▁ensure 0.9794921875
▁access 2.396484375
ibility 0.24267578125
▁and 0.84619140625
▁afford 0.052764892578125
ability 0.003597259521484375
▁for 0.966796875
▁patients 0.166015625
▁glob 2.892578125
ally 1.0371208190917969e-05
. 0.00579833984375
<0x0A> 0.059844970703125
Des 1.001953125
p 2.384185791015625e-05
ite 1.6808509826660156e-05
▁the 1.4072265625
▁hur 1.9658203125
d 2.1457672119140625e-06
les 5.316734313964844e-05
▁British 2.515625
▁Bi 0.001453399658203125
ote 1.6689300537109375e-05
ch 0.0005259513854980469
▁faces 0.26953125
, 0.345947265625
▁hopes 7.73828125
▁remain 0.300537109375
▁high 0.058837890625
▁for 0.219482421875
▁Mar 0.9931640625
im 0.0011138916015625
ast 0.00011992454528808594
at 0.0001169443130493164
' 0.3046875
s 0.00017058849334716797
▁block 7.88671875
b 0.00040793418884277344
uster 0.0010995864868164062
▁potential 0.11590576171875
. 0.058563232421875
▁The 0.57568359375
▁drug 0.94970703125
' 0.349853515625
s 2.3365020751953125e-05
▁effic 3.109375
acy 1.919269561767578e-05
▁in 0.587890625
▁early 1.23828125
▁clin 0.82080078125
ical 6.008148193359375e-05
▁tri 0.0037078857421875
als 3.6954879760742188e-06
, 1.6806640625
▁couple 1.4951171875
d 3.4570693969726562e-06
▁with 6.210803985595703e-05
▁on 3.38671875
going 0.002117156982421875
▁research 0.435302734375
▁and 0.779296875
▁development 0.44873046875
▁efforts 0.86328125
, 0.057342529296875
▁show 5.57421875
cases 1.96484375
▁British 3.083984375
▁Bi 0.00170135498046875
ote 1.7404556274414062e-05
ch 0.0005474090576171875
' 0.0142974853515625
s 0.00014209747314453125
▁commit 0.25146484375
ment 2.9325485229492188e-05
▁to 0.01403045654296875
▁adv 1.8046875
ancing 0.0022678375244140625
▁cancer 0.599609375
▁treatment 0.58154296875
. 0.36669921875
▁The 1.642578125
▁company 0.1405029296875
' 0.32275390625
s 9.524822235107422e-05
▁determ 2.77734375
ination 3.6954879760742188e-06
▁to 0.291748046875
▁overcome 0.7685546875
▁regul 1.5029296875
atory 0.00012362003326416016
▁requirements 4.58203125
, 0.125732421875
▁address 1.3408203125
▁potential 1.56640625
▁side 0.10382080078125
▁effects 0.0019741058349609375
, 0.041412353515625
▁demonstrate 7.45703125
▁superior 0.2900390625
ity 0.00725555419921875
▁over 0.0850830078125
▁existing 0.32666015625
▁ther 0.83349609375
ap 0.00011491775512695312
ies 6.079673767089844e-06
▁and 3.607421875
▁establish 1.2255859375
▁a 4.13671875
▁solid 4.328125
▁market 3.197265625
▁presence 1.3125
▁all 6.94921875
▁contribute 2.6640625
▁to 0.026336669921875
▁the 1.0517578125
▁world 9.2890625
' 0.86474609375
s 0.00013458728790283203
▁eager 6.3515625
▁anticip 0.044677734375
ation 0.00013780593872070312
▁of 0.48583984375
▁Mar 0.447265625
im 0.0017976760864257812
ast 0.00031948089599609375
at 0.0005025863647460938
' 0.08489990234375
s 0.00010287761688232422
▁future 2.984375
▁success 1.71484375
. 0.10247802734375
